285 related articles for article (PubMed ID: 18562811)
41. Strategies to preserve the use of statins in patients with previous muscular adverse effects.
Reinhart KM; Woods JA
Am J Health Syst Pharm; 2012 Feb; 69(4):291-300. PubMed ID: 22302254
[TBL] [Abstract][Full Text] [Related]
42. [Specific considerations on the prescription and therapeutic interchange of statins].
García-Sabina A; Gulín-Dávila J; Sempere-Serrano P; González-Juanatey C; Martínez-Pacheco R
Farm Hosp; 2012; 36(2):97-108. PubMed ID: 21820929
[TBL] [Abstract][Full Text] [Related]
43. Prevalence of potentially severe drug-drug interactions in ambulatory patients with dyslipidaemia receiving HMG-CoA reductase inhibitor therapy.
Rätz Bravo AE; Tchambaz L; Krähenbühl-Melcher A; Hess L; Schlienger RG; Krähenbühl S
Drug Saf; 2005; 28(3):263-75. PubMed ID: 15733030
[TBL] [Abstract][Full Text] [Related]
44. Lipid management in the geriatric patient.
Nair AP; Darrow B
Endocrinol Metab Clin North Am; 2009 Mar; 38(1):185-206. PubMed ID: 19217519
[TBL] [Abstract][Full Text] [Related]
45. An assessment of statin safety.
McKenney JM
Am J Manag Care; 2006 Oct; 12(11 Suppl):S310-7. PubMed ID: 17042673
[TBL] [Abstract][Full Text] [Related]
46. Does statin therapy initiation increase the risk for myopathy? An observational study of 32,225 diabetic and nondiabetic patients.
Nichols GA; Koro CE
Clin Ther; 2007 Aug; 29(8):1761-70. PubMed ID: 17919557
[TBL] [Abstract][Full Text] [Related]
47. Statin safety: an overview and assessment of the data--2005.
Bays H
Am J Cardiol; 2006 Apr; 97(8A):6C-26C. PubMed ID: 16581330
[TBL] [Abstract][Full Text] [Related]
48. Evidence-based prediction of statin use with lipid-panel data from the National Health and Nutrition Examination Survey.
Gorevski E; Bian B; Kelton CM; Martin Boone JE; Guo JJ
Value Health; 2012 Jan; 15(1):32-8. PubMed ID: 22264969
[TBL] [Abstract][Full Text] [Related]
49. Meta-analysis of drug-induced adverse events associated with intensive-dose statin therapy.
Silva M; Matthews ML; Jarvis C; Nolan NM; Belliveau P; Malloy M; Gandhi P
Clin Ther; 2007 Feb; 29(2):253-60. PubMed ID: 17472818
[TBL] [Abstract][Full Text] [Related]
50. Statin-related myotoxicity.
Fernandes V; Santos MJ; Pérez A
Endocrinol Nutr; 2016 May; 63(5):239-49. PubMed ID: 27005745
[TBL] [Abstract][Full Text] [Related]
51. Nonstatin therapies for management of dyslipidemia: a review.
Sando KR; Knight M
Clin Ther; 2015 Oct; 37(10):2153-79. PubMed ID: 26412799
[TBL] [Abstract][Full Text] [Related]
52. The safety of aggressive statin therapy: how much can low-density lipoprotein cholesterol be lowered?
Jacobson TA
Mayo Clin Proc; 2006 Sep; 81(9):1225-31. PubMed ID: 16970219
[TBL] [Abstract][Full Text] [Related]
53. Neuromuscular complications of statins.
Ahn SC
Phys Med Rehabil Clin N Am; 2008 Feb; 19(1):47-59, vi. PubMed ID: 18194749
[TBL] [Abstract][Full Text] [Related]
54. Statin drugs: reducing cardiovascular risk in older adults.
McLain K; Edlund BJ
J Gerontol Nurs; 2012 Oct; 38(10):9-13. PubMed ID: 22998096
[TBL] [Abstract][Full Text] [Related]
55. The influence of statin characteristics on their safety and tolerability.
De Angelis G
Int J Clin Pract; 2004 Oct; 58(10):945-55. PubMed ID: 15587774
[TBL] [Abstract][Full Text] [Related]
56. Statins for primary prevention of cardiovascular and cerebrovascular events in diabetic patients without established cardiovascular diseases: a meta-analysis.
Chen YH; Feng B; Chen ZW
Exp Clin Endocrinol Diabetes; 2012 Feb; 120(2):116-20. PubMed ID: 22187291
[TBL] [Abstract][Full Text] [Related]
57. Optimizing Cholesterol Treatment in Patients With Muscle Complaints.
Rosenson RS; Baker S; Banach M; Borow KM; Braun LT; Bruckert E; Brunham LR; Catapano AL; Elam MB; Mancini GBJ; Moriarty PM; Morris PB; Muntner P; Ray KK; Stroes ES; Taylor BA; Taylor VH; Watts GF; Thompson PD
J Am Coll Cardiol; 2017 Sep; 70(10):1290-1301. PubMed ID: 28859793
[TBL] [Abstract][Full Text] [Related]
58. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
Sahebkar A; Watts GF
Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550
[TBL] [Abstract][Full Text] [Related]
59. Is there value in liver function test and creatine phosphokinase monitoring with statin use?
Sniderman AD
Am J Cardiol; 2004 Nov; 94(9A):30F-34F. PubMed ID: 15519289
[TBL] [Abstract][Full Text] [Related]
60. An examination of the effect of cytochrome P450 drug interactions of hydroxymethylglutaryl-coenzyme A reductase inhibitors on health care utilization: a Canadian population-based study.
Einarson TR; Metge CJ; Iskedjian M; Mukherjee J
Clin Ther; 2002 Dec; 24(12):2126-36. PubMed ID: 12581550
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
